112 related articles for article (PubMed ID: 7987850)
1. DNA binding and transactivation activity of A-myb, a c-myb-related gene.
Ma XP; Calabretta B
Cancer Res; 1994 Dec; 54(24):6512-6. PubMed ID: 7987850
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional activation by human c-myb and v-myb genes.
Kalkbrenner F; Guehmann S; Moelling K
Oncogene; 1990 May; 5(5):657-61. PubMed ID: 2189102
[TBL] [Abstract][Full Text] [Related]
3. The human A-myb protein is a strong activator of transcription.
Golay J; Loffarelli L; Luppi M; Castellano M; Introna M
Oncogene; 1994 Sep; 9(9):2469-79. PubMed ID: 8058310
[TBL] [Abstract][Full Text] [Related]
4. The chicken A-myb protein is a transcriptional activator.
Foos G; Grimm S; Klempnauer KH
Oncogene; 1994 Sep; 9(9):2481-8. PubMed ID: 8058311
[TBL] [Abstract][Full Text] [Related]
5. Interaction of the v-and c-Myb proteins with regulatory sequences of the human c-myc gene.
Zobel A; Kalkbrenner F; Guehmann S; Nawrath M; Vorbrueggen G; Moelling K
Oncogene; 1991 Aug; 6(8):1397-407. PubMed ID: 1679531
[TBL] [Abstract][Full Text] [Related]
6. Fli-1b is generated by usage of differential splicing and alternative promoter.
Dhulipala PD; Lee L; Rao VN; Reddy ES
Oncogene; 1998 Sep; 17(9):1149-57. PubMed ID: 9764825
[TBL] [Abstract][Full Text] [Related]
7. Murine A-myb: evidence for differential splicing and tissue-specific expression.
Mettus RV; Litvin J; Wali A; Toscani A; Latham K; Hatton K; Reddy EP
Oncogene; 1994 Oct; 9(10):3077-86. PubMed ID: 8084617
[TBL] [Abstract][Full Text] [Related]
8. Myb binding sites within the N-ras promoter repress transcription.
Ganter B; Lipsick JS
Oncogene; 1997 Jul; 15(2):193-202. PubMed ID: 9244354
[TBL] [Abstract][Full Text] [Related]
9. Solution structure of the B-Myb DNA-binding domain: a possible role for conformational instability of the protein in DNA binding and control of gene expression.
McIntosh PB; Frenkiel TA; Wollborn U; McCormick JE; Klempnauer KH; Feeney J; Carr MD
Biochemistry; 1998 Jul; 37(27):9619-29. PubMed ID: 9657674
[TBL] [Abstract][Full Text] [Related]
10. The conserved DNA binding domain mediates similar regulatory interactions for A-Myb, B-Myb, and c-Myb transcription factors.
Rushton JJ; Ness SA
Blood Cells Mol Dis; 2001; 27(2):459-63. PubMed ID: 11259168
[TBL] [Abstract][Full Text] [Related]
11. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide-releasing agents and cGMP analogues inhibit murine erythroleukemia cell differentiation and suppress erythroid-specific gene expression: correlation with decreased DNA binding of NF-E2 and altered c-myb mRNA expression.
Suhasini M; Boss GR; Pascual FE; Pilz RB
Cell Growth Differ; 1995 Dec; 6(12):1559-66. PubMed ID: 9019161
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator.
Bessa M; Saville MK; Watson RJ
Oncogene; 2001 Jun; 20(26):3376-86. PubMed ID: 11423988
[TBL] [Abstract][Full Text] [Related]
14. Resistance to apoptosis in CTLL-2 cells overexpressing B-Myb is associated with B-Myb-dependent bcl-2 induction.
Grassilli E; Salomoni P; Perrotti D; Franceschi C; Calabretta B
Cancer Res; 1999 May; 59(10):2451-6. PubMed ID: 10344757
[TBL] [Abstract][Full Text] [Related]
15. Induction of B cell lymphomas by overexpression of a Myb oncogene truncated at either terminus.
Press RD; Wisner TW; Ewert DL
Oncogene; 1995 Aug; 11(3):525-35. PubMed ID: 7630637
[TBL] [Abstract][Full Text] [Related]
16. The carboxy-terminal domain of c-Myb activates reporter gene expression in yeast.
Seneca S; Punyammalee B; Sureau A; Perbal B; Dvorák M; Crabeel M
Oncogene; 1993 Sep; 8(9):2335-42. PubMed ID: 8361752
[TBL] [Abstract][Full Text] [Related]
17. Flexibility in the second half-site sequence recognised by the c-Myb R2 domain--in vitro and in vivo analysis.
Ording E; Bergholtz S; Brendeford EM; Jamin N; Gabrielsen OS
Oncogene; 1996 Sep; 13(5):1043-51. PubMed ID: 8806694
[TBL] [Abstract][Full Text] [Related]
18. Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP).
Chang CH; Scott GK; Baldwin MA; Benz CC
Oncogene; 1999 Jun; 18(25):3682-95. PubMed ID: 10391676
[TBL] [Abstract][Full Text] [Related]
19. Construction of an artificial tandem protein of the c-Myb DNA-binding domain and analysis of its DNA binding specificity.
Oda M; Furukawa K; Sarai A; Nakamura H
Biochem Biophys Res Commun; 1999 Aug; 262(1):94-7. PubMed ID: 10448074
[TBL] [Abstract][Full Text] [Related]
20. An alternatively spliced isoform of B-Myb is a transcriptional inhibitor.
Horstmann S; Ferrari S; Klempnauer KH
Oncogene; 2000 Nov; 19(48):5428-34. PubMed ID: 11114719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
